These results showed that the USP14/IDO1 axis correlated negatively with antitumor immune infiltration in CRC tumors, further supporting the view that inhibition of USP14 could enhance CRC sensitivity to anti-PD-1 therapy (Fig. 7f). The gene discussed is IDO1; the disease is colorectal carcinoma.